Taxotere, Docetaxel
Taxotere, Docetaxel Newswire (Page 8)

Taxotere, Docetaxel Newswire (Page 8)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 8)

Results 141 - 160 of 695 in Taxotere, Docetaxel (generic)

  1. Now Available: OncoEthix SA - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story

    May 21, 2015 | PR-inside.com

    The company develops drugs for cancer treatment. Its OTX015 is a BET bromodomain inhibitor for the treatment of advanced hematologic malignancies.

    Comment?

  2. Diabetes Drug Metformin Increases Survival in Ovarian Cancer PatientsRead the original story

    May 21, 2015 | P&T Community

    Several recent studies have suggested that metformin, an established drug developed to treat patients with type-2 diabetes, may provide significant benefits, including increased survival, in patients with advanced cancers. An analysis of combined results from these earlier studies found that the use of metformin was associated with a significant decrease in cancer risk, tumor burden, and cancer mortality.

    Comment?

  3. Early Chemo May Boost Survival in Advanced Prostate CancerRead the original story w/Photo

    May 14, 2015 | WebMD

    Starting the chemotherapy drug docetaxel at the same time as hormone therapy can improve survival for men with newly diagnosed, advanced prostate cancer , British researchers say. Currently, chemotherapy is generally given after hormone therapy stops working.

    Comment?

  4. Docetaxel Along With Standard Treatment Gives Prostate Cancer Patients Two Years LongerRead the original story w/Photo

    May 15, 2015 | Medical Daily

    Metastatic prostate cancer patients who receive standard hormone treatment along with docetaxel chemotherapy may live up to two years longer, according to clinical trial results from an ongoing study . Cardiff and Warwick University researchers used 2,692 participants in the study.

    Comment?

  5. Just Published: "NanoCarrier Co., Ltd. (4571) - Pharmaceuticals &...Read the original story

    May 14, 2015 | PR-inside.com

    The company researches, develops and produces pharmaceuticals using micellar nanoparticles technology. It develops drugs in the field of oncology.

    Comment?

  6. Prostate cancer drug 'extends lives'Read the original story w/Photo

    May 13, 2015 | BBC News

    Early treatment with a chemotherapy drug extends the lives of patients with advanced prostate cancer by nearly two years, a major study shows. But results, to be presented at the American Society of Clinical Oncology, will show earlier treatment can extend life expectancy from 43 to 65 months.

    Comment?

  7. Novogen Limited Release: Anisina Confirmed As Effective Anti-Cancer Agent In Animal StudiesRead the original story

    May 13, 2015 | BioSpace

    The Company announced recently that Anisina was a potent cytotoxic in vitro against human melanoma cells, and in particular that this effect was unaffected by the mutational status of the melanoma cells, particularly the common Braf gene status. The purpose of the pre-clinical study was to provide evidence that this potent anti-cancer effect could be transferred to the whole animal.

    Comment?

  8. Genentech??'s Investigational Immunotherapy MPDL3280A Doubled The...Read the original story

    May 13, 2015 | BioSpace

    Genentech, a member of the Roche Group , today announced interim results from a global, randomized Phase II study in people with previously treated non-small cell lung cancer . The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy.

    Comment?

  9. New Enzalutamide Data in Triple-Negative Breast Cancer to Be...Read the original story w/Photo

    May 14, 2015 | Market Wire

    Title: Results from a phase 2 study of enzalutamide, an androgen receptor inhibitor, in advanced AR+ triple-negative breast cancer capsules XTANDI is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic castration-resistant prostate cancer . Enzalutamide Mechanism of Action Enzalutamide is an androgen receptor inhibitor that acts on three different steps in the androgen receptor signaling pathway.

    Comment?

  10. Genentech's Investigational Immunotherapy MPDL3280A Doubled the...Read the original story

    May 13, 2015 | Freshnews

    Genentech, a member of the Roche Group , today announced interim results from a global, randomized Phase II study in people with previously treated non-small cell lung cancer . The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy.

    Comment?

  11. Aclidinium bromide/formoterol in COPD: Added benefit for certain patient groupsRead the original story w/Photo

    May 12, 2015 | PhysOrg Weblog

    The fixed-dose combination aclidinium bromide/formoterol has been approved since November 2014 for long-term treatment of adults with chronic obstructive pulmonary disease . The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug combination offers an added benefit over the appropriate comparator therapy.

    Comment?

  12. Cerulean to Present at the UBS Global Healthcare ConferenceRead the original story

    May 12, 2015 | Freshnews

    Cerulean Pharma Inc. today announced that Christopher D. T. Guiffre, J.D., M.B.A., President & Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York on Tuesday, May 19, 2015, at 9:00 a.m. ET. A live audio webcast of the presentation will be available on the "Investors" section of the Company's website, www.ceruleanrx.com with the replay available for two weeks following the presentation.

    Comment?

  13. BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate UpdateRead the original story

    May 7, 2015 | Freshnews

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results and business highlights for the quarter ended March 31, 2015. "We had a strong start to 2015 and executed across all phases of our business," said Andrew Hirsch, president and chief executive officer of BIND Therapeutics.

    Comment?

  14. Astellas Pharma Inc. Announces New Data To Be Presented During Late...Read the original story

    May 4, 2015 | BioSpace

    Also being presented during the late breaking plenary session are data from the Phase 3b BESIDE study, a randomized, double-blind, international study designed to evaluate the efficacy and safety of solifenacin with mirabegron as an add-on therapy in OAB patients.

    Comment?

  15. Cerulean to Present at the Deutsche Bank 40th Annual Health Care ConferenceRead the original story

    Apr 30, 2015 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced that Christopher D. T. Guiffre, JD, MBA, Cerulean's President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Deutsche Bank 40th Annual Health Care Conference in Boston on Thursday, May 7, 2015 at 9:20 a.m. ET. A live webcast of the presentation will be available in the "Investors" section of the Company's website: www.ceruleanrx.com .

    Comment?

  16. Celator Pharmaceuticals, Inc. To Report First Quarter 2015 Financial Results On May 7, 2015Read the original story

    Apr 29, 2015 | BioSpace

    The live webcast of the call can be accessed in the Investors section of the Company's website at www.celatorpharma.com . An archived webcast will be available on the Company's website beginning approximately two hours after the event.

    Comment?

  17. OncoGenex Pharmaceuticals Inc. Announces Custirsen Phase 3 "ENSPIRIT" Trial UpdateRead the original story

    Apr 29, 2015 | BioSpace

    Protocol Amended to Provide Faster Assessment of Survival Outcomes with Reduced Trial Size BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2015 /CNW/ -- OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer .

    Comment?

  18. A holistic approach to targeting disease with polymeric nanoparticlesRead the original story

    Apr 30, 2015 | Nature Reviews Drug Discovery

    In Box 1 on page 241, BIND-014 was described as being loaded with doxorubicin, when it is in fact loaded with docetaxel, as described in Table 1 on page 242. This has been corrected in the online version.

    Comment?

  19. Cerulean to Host First-Quarter 2015 Conference Call on May 6Read the original story

    Apr 29, 2015 | Freshnews

    Cerulean Pharma Inc. , a leader in Dynamic Tumor Targeting, today announced it will provide an update on corporate activities for the first-quarter 2015 on May 6. Christopher D. T. Guiffre, JD, MBA, President and Chief Executive Officer, and Paul Friedman, M.D., Executive Chairman will conduct a conference call at 4:30 p.m. ET that day to provide a business update and review the Company's first-quarter financial results. The call can be accessed by dialing 831-3031 or 637-1284 prior to the start of the call and referencing conference ID 33646103.

    Comment?

  20. Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging...Read the original story

    Apr 29, 2015 | BioMed Central

    Department of Molecular Cell Biology and Toxicology, Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment Cancer Center; School of Public Health, Nanjing Medical University, Nanjing 210029, China Background DNA damage repair genes JWA, XRCC1 and BRCA1 were associated with clinical outcomes and could convert the response to the cisplatin-based therapy in some carcinomas. The synergistic effects of JWA, XRCC1 and BRCA1 mRNA expression on personalized therapy remain unknown in advanced esophageal squamous cell carcinoma .

    Comment?